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Abstract 
Purpose: To investigate microRNA-383 (miR-383) as a therapeutic target for the management of colon 
cancer. 
Methods: Total RNA was isolated using RNeasy RNA isolation kit according to the manufacturer’s 
instructions. cDNA was synthesized using RevertAid cDNA synthesis kit. Expression analysis was 
carried out by quantitative real-time polymerase chain reaction (RT-PCR). Cell proliferation was 
examined using CellTiter 96 AQueous One Solution Cell Proliferation Assay system, while apoptosis 
was detected by 4',6-diamidino-2-phenylindole (DAPI) and annexin V/PI double staining followed by flow 
cytometry. The miR-383 target was delimited using TargetScan software. Protein expression analysis 
was carried out by western blotting. 
Results: The results indicate that miR-383 was highly expressed in colon cancer cells. Down-regulation 
of miR-383 inhibited cancer cell proliferation, and promoted apoptosis and cell cycle arrest. 
Furthermore, in silico analysis revealed caspase-2 gene to be the downstream target of miR-383, a 
finding that was further confirmed by western blotting. 
Conclusion: The results reveal that miR-383 may be an important target to tackle the increasing 
incidence of colon cancer. Thus, drugs that target miR-383 and inhibit its expression can potentially be 
developed for the treatment of colon cancer. 
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Among the gastrointestinal cancers, colon cancer 
is one of most prevalent types [1]. Owing to the 
drastic alterations in human life styles, the 
incidence of cancer has significantly increased 
globally. Studies have reported that colon cancer 
is the second major reason for cancer-related 
deaths among all malignant tumors [2]. Currently, 
the treatment of colon cancer involves surgery, 
followed by chemotherapy. However, the 
prognosis for colon cancer is very poor, and the 
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mortality rate is high [3]. Therefore, there is an 
urgent need to develop novel treatment 
strategies or explore novel targets to limit the 
increasing incidence of colon cancer. MicroRNAs 
(miRNAs) include a large family of small 
noncoding RNAs that are involved in the 
inhibition of protein synthesis by binding to 
different sites in the 3'-untranslated region (3'-
UTR) of target genes. Therefore miRNAs exhibit 
remarkable biological significance and play a role 
in diverse cellular process [4,5]. 
 
Among several human miRNAs associated with 
cancers, hsa-microRNA-383-5p (miR-383) has 
been reported to be principally upregulated. 
Thus, it has been reported to promote tumor 
progression in several cancers, including, but not 
limited to, gastric cancer and glioma [6,7].  
 
In the present study, the expression of miR-383 
was determined in different colon cancer cell 
lines, and miR-383 was explored as a potential 





Colon cancer cell lines and culture conditions 
 
All the chemicals and reagents were obtained 
from Sigma-Aldrich Co. (St. Louis, MO, USA) 
unless otherwise mentioned. Primary and 
secondary antibodies were purchased from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). Six human colon cancer cell lines, CCL-
233, CL-188, CL-231, HTB-37, HTB-39, and 
CRL-7280, and one normal cell line, CRL-1459, 
were purchased from Type Culture Collection of 
Chinese Academy of Sciences (Shanghai, 
China). Cell culture was carried in RPMI-1640 
medium containing 10% fetal bovine serum, 
appropriate antibiotics, with maintenance in a 
humidified atmosphere containing 5 % CO2. All 
of the reagents were procured from Hyclone. 
 
RNA isolation, cDNA synthesis, and 
expression analysis 
 
Total RNA was isolated using the RNeasy kit 
according to the manufacturer’s instructions. 
Quality check of the RNA samples was 
performed by measuring the absorbance using a 
NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies), calculating the 260 
nm/280 nm ratio and separation on 1 % agarose 
gels. DNA contamination was removed by 
DNase I (Fermentas) treatment. cDNA was 
synthesized using the RevertAid cDNA synthesis 
kit (Fermentas) according to the manufacturer’s 
protocol. 
The relative quantification method (ΔΔ-CT) was 
used to determine the quantitative variation 
among the replicates examined. β-Actin was 
used as a positive control to normalize the data. 
 
Inhibition of miR-383 in colon cancer cells 
 
The inhibitor of human miR-383 (MiR383-In, 107 
units/mL) and its non-specific miRNA lentivirus 
(MiR-C, 107 units/mL) were obtained from 
RiboBio (RiboBio, China). CL-188 cells were 
incubated with lentiviral particles (10 mL/1000 
cells; multiplicity of infection = 10–15) and 
polybrene (8 mg/mL) for 48 h. Thereafter, the 
media were replaced, and CL-188 cells were 
incubated for another 3–7 days for stabile 
transduction. The cells were then passaged and 




Oral cancer CL-188, microRNA-inhibited CL-188 
cancer cells, and normal CRL-1459 were 
separately seeded into 96-well plates, with each 
well containing approximately 5, 000 cells and 
the cells permitted to grow for 5 days. Thereafter, 
cell proliferation was examined using the cell 
proliferation assay kit (Promega USA) according 
to the manufacturer’s guidelines. At every 24-h 
interval, 15 mL of MTT solution was 
administrated to each well for 2 h at 37 °C. The 





Colon cancer CL-188, microRNA-inhibited CL-
188 cancer cells, and normal CRL-1459 cells 
were separately seeded at density of 2 ਀ 105 
cells/well in 6-well plates and were treated with 
different concentrations of cisplatin and then 
were incubated for 24 h. Apoptosis was 
examined by incubating the cells in 6-well plates 
for 24 h with DAPI.  
 
The cells were then washed with PBS, fixed in 10 
% formaldehyde, followed by another wash with 
PBS. The DAPI-stained cells were then 
examined by fluorescence microscopy. For 
annexin V/PI staining, a similar procedure to that 
of DAPI was followed except the cells were 
treated with annexin V/PI and were investigated 
by flow cytometry. 
 
Identification of the miR-383 target 
 
To gain insight into the potential target of miR-
383, the TargetScan search program was used. 
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Total protein from the cancer cells was isolated 
using RIPA lysis buffer. The proteins were 
quantified using the BSA protein assay kit, and 
equal protein extracts from each group were 
resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, followed by 
transfer to a polyvinylidene fluoride membrane. 
Next, the membrane was blocked with 5 % non-
fat milk and incubated at room temperature for 1 
h. Thereafter, the membranes were incubated 
with the primary antibody at 4 °C overnight, 
followed by washing in washing buffer and 
incubation with the secondary antibody for 1 h. 
The protein bands of interest were visualized 





The experiments were repeated three times, and 
the values were expressed as means ± SD. 
GraphPad 7 software was used for statistical 
analysis. The values were considered significant 





miR-383 is upregulated in colon cancer cell 
lines 
 
The expression of miR-383 was determined in 
six different oral cancer cell lines (CCL-233, CL-
188, CL-231, HTB-37, HTB-39, CRL-7280) and 
one normal cell line CRL-1459 (Figure 1) by 
quantitative RT-PCR analysis. The results of this 
study revealed that the expression of miR-383 
was considerably upregulated in all the oral 
cancer cell lines compared with that in the 
control. These results of expression analysis 
indicated that miR-383 may prove to be an 
important therapeutic target. 
 
Inhibition of miR-383 promotes growth 
inhibition  
 
To understand the role of miR-383 in colon 
cancer, its expression was inhibited in colon 
cancer CL-188 cells through lentiviral 
transduction. The results indicated that the 
inhibition of miR-383 caused significant inhibition 
of the growth of colon cancer cells as evident 
from the proliferation assay (Figure 2). These 
results suggest that miR-383 is required for the 
proliferation of colon cancer cells. 
 
 
Figure 1: Expression of miR-383 in normal colon and 
colon cancer cell lines. The experiments were carried 
out in triplicate and were expressed as means ± SD. 
The values were considered significant at *p < 0.01, 
**p < 0.001, and ***p < 0.0001 
 
 
Figure 2: Proliferation of control colon cancer CL-188 
cells with normal microRNA-383 expression and CL-
188 cells with inhibited microRNA-383 expression. The 
experiments were carried out in triplicate and were 
expressed as means ± SD. The values were 
considered significant at *p < 0.01, **p < 0.001, and 
***p < 0.0001 
 
Inhibition of miR-383 promotes apoptosis 
 
The results indicated that the inhibition of miR-
383 results in the inhibition of cell growth. 
Therefore, to ascertain whether the 
antiproliferative effects are due to the induction of 
apoptosis, DAPI staining was carried out. 
Interestingly, the results indicated that the 
inhibition of miR-383 in colon cancer CL-188 
cells led to the triggering of apoptosis (Figure 3). 
Furthermore, the apoptotic cell populations were 
examined by annexin V/PI double staining. The 
results showed that the apoptotic cell distribution 
was 39.6 % in miRNA-inhibited cells compared 
with 2.61 % in control CL-188 cells (Figure 4). 
 
Inhibition of miR-383 induces cell cycle arrest 
 
The cell cycle phase distribution in miR-383 
silenced and control CL-188 colon cancer cells 
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was further determined. The results suggested 
that miR-383 inhibition promotes G2/M cell cycle 
arrest as evident by the accumulation of a higher 
number of CL-188 oral cancers in the G2 phase 




Figure 3: Detection of apoptosis by DAPI staining in 
control colon cancer CL-188 cells with normal miR-383 
expression and CL-188 cells with inhibited miR-383 





Figure 4: Estimation of the apoptotic cell distribution 
by annexin V/PI staining in control colon cancer CL-
188 cells with normal miR-383 expression and CL-188 
cells with inhibited miR-383 expression. The 




Figure 5: Cell cycle analysis of control colon cancer 
CL-188 cells with normal miR-383 expression and CL-
188 cells with inhibited miR-383 expression. The 
experiments were carried out in triplicate 
 
miR-383 targets the caspase 2 gene 
 
To identify the downstream target gene of miR-
383, the target scan (www.targetscan.org) server 
was used. CASP2 was observed to be a 
potential target gene of miR-383. The 3ʹ-UTR 
DNA segment of CASP2 was found to be 
complimentary to the binding of miR-383 (Fig. 
5A). Next, to further confirm that CASP2 is the 
actual target of miR-383, the expression of the 
CASP2 gene in colon cancer CL-188 and 
miRNA-inhibited CL-188 cancer cells was 
examined by western blotting. The results 
revealed that miR-383 inhibition considerably 
enhanced CASP-2 gene expression in CL-188 
cells, further validating that the CASP-2 gene is 





Figure 6: The miR-383 target CASP-2 gene. (A) 
TargetScan revealed the CASP-2 gene as the 
potential target of miR-383. (B) Expression of CASP-2 
protein in control colon cancer CL-188 cells with 
normal miR-383 expression (L1) and in CL-188 cells 
with inhibited miR-383 expression (L2). The 




It is now well established in the literature that 
miRNAs play vital roles in human cancer 
development and its progression through 
different stages [8]. The expression of miRNAs 
may be either enhanced or suppressed 
depending on whether they promote or suppress 
the tumorigenesis and progression of cancers. 
Recently, miRNAs have been considered 
important therapeutic targets for the 
management of several types of cancers [9]. 
miR-383 has been reported to play vital roles in 
human cancers such as ovarian cancer [10]. 
However, the exact role and underlying 
mechanism of miRNA-383 in the development of 
cancer progression have not been thoroughly 
studied. 
 
In the present study, the expression of miR-383 
was investigated in six different colon cancer cell 
lines and one normal cell line. The results of this 
study revealed that the expression of miR-383 
was highly upregulated in all the colon cancer 
cell lines. The results of this study agree with 
previous study data wherein the expression of 
miR-383 was observed to be highly enhanced in 
several cancers. For instance, Liu et al reported 
that the expression of miR-383 was highly 
enhanced in ovarian cancer cells [10]. More 
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interestingly, some studies have even reported 
that the expression of miR-383 is down-regulated 
in cancers like gastric cancer and glioma [6,7]. 
These results, as well as those of previous 
studies, clearly indicate that miR-383 may be an 
important therapeutic target. 
 
To confirm the role of miR-383 in colon cancer, 
silencing of microRNA expression in CL-188 
colon cancer cells was performed by lentiviral 
transduction. The inhibition of miR-131 was 
demonstrated to inhibit the cell proliferation of 
CL-188 cells compared with that in the control. 
Furthermore, to gain insights into the mechanism 
by which miR-383 promotes the inhibition of cell 
proliferation, DAPI staining was carried out. The 
results indicated that the inhibition of miR-383 
triggered apoptosis in CL-188 cells. The latter 
finding was further confirmed by annexin V/PI 
staining, which revealed that miR-383 caused 39 
% of apoptosis compared with 3.4 % in the 
control. Apoptosis is an important mechanism by 
which cancerous cells are removed from the 
body. Several anticancer agents have been 
reported to exhibit anticancer activities via the 
induction of apoptosis. In addition, apoptosis is 
an important mechanism to avoid the 
development of drug resistance [11]. Moreover, 
besides apoptosis, cell cycle arrest is considered 
an important mechanism by which anticancer 
agents exert their effects [12]. 
 
The results of the present study clearly showed 
that the inhibition of miR, leading to G2/M cell 
cycle arrest in colon cancer CL-188 cells, was 
quite evident from the increased number of colon 
cancer cells in the G2 phase of the cell cycle. 
Next, the online software TargetScan was used 
to delimit the potential target of miR-383. The 
results showed CASP-2, a member of cysteine 
protease family, was the downstream target gene 
of miR-383. Recent studies have demonstrated 
that CASP-2 protein triggers cell death in human 
cancer cells, possibly via the suppression of fatty 
acid synthase [13]. To further confirm the 
involvement of CASP-2 in miR-383-prompted cell 
death, we investigated the expression of CASP-2 
in CL-188 cells with silenced miR-383. The 
results indicated that the expression of CASP-2 
was highly enhanced in these cells, confirming 
the involvement of CASP-2 in microRNA-




The findings of this study indicate that miR-383 
may be an important target to stem the 
increasing incidence of colon cancer. Thus, 
drugs that target miR-383 and inhibit its 
expression can potentially be developed for the 
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